Determination of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry

被引:43
作者
Kanazawa, H
Okada, A
Matsushima, Y
Yokota, H
Okubo, S
Mashige, F
Nakahara, K
机构
[1] Kyoritsu Coll Pharmaceut Sci, Minato Ku, Tokyo 1058512, Japan
[2] Univ Tokyo, Dept Lab Med, Bunkyo Ku, Tokyo 1138655, Japan
关键词
sonic spray ionization; interfaces; LC-MS; omeprazole; cytochromes; benzimidazoles;
D O I
10.1016/S0021-9673(01)01508-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Omeprazole is a benzimidazole compound that acts as a proton-pump inhibitor. Because the metabolism of omeprazole is mainly catalyzed by cytochrome P-450 (CYP) 3A4 and CYP2C19, the genetic polymorphism of CYP2C19 could be of clinical concern in the treatment of acid-related diseases with omeprazole. Therefore, a reliable method for omeprazole phenotyping is desirable in clinical situations. This study has demonstrated the determination of omeprazoie and its metabolites in human plasma by liquid chromatography-three-dimensional quadrupole mass spectrometry with a sonic spray ionization interface. The analytical column was YMC-Pack Pro C-18(50X2.0 mm I.D.) using acetonitrile-50 mm ammonium acetate (pH 7.25) (1:4) at a flow-rate of 0.2 ml /min. The drift voltage was 30 V The sampling aperture was heated at 110 degreesC and Shield temperature was 230 degreesC. In the mass spectrum, the molecular ions of omeprazole, hydroxyomeprazole and omeprazole sulfone were clearly observed as base peaks. This method is sufficiently sensitive and accurate for pharmacokinetic studies of omeprazol. (C) 2002 Elsevier Science B V All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 23 条
  • [1] Äbelö A, 2000, DRUG METAB DISPOS, V28, P966
  • [2] SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS
    ANDERSSON, T
    REGARDH, CG
    DAHLPUUSTINEN, ML
    BERTILSSON, L
    [J]. THERAPEUTIC DRUG MONITORING, 1990, 12 (04) : 415 - 416
  • [3] ANDERSSON T, 1995, PHARMACOGENETICS, V5, P358
  • [4] Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin
    Bottiger, Y
    Tybring, G
    Gotharson, E
    Bertilsson, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) : 384 - 391
  • [5] INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19
    CHANG, M
    TYBRING, G
    DAHL, ML
    GOTHARSON, E
    SAGAR, M
    SEENSALU, R
    BERTILSSON, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (05) : 511 - 518
  • [6] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
  • [7] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
  • [8] Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
    Furuta, T
    Takashima, M
    Shirai, N
    Xiao, F
    Hanai, H
    Ohashi, K
    Ishizaki, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (06) : 684 - 689
  • [9] Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C Upsilon P2C19(m1) in exon 5 and C Upsilon P2C19(m2) in exon 4, in Japanese subjects
    Ieiri, I
    Kubota, T
    Urae, A
    Kimura, M
    Wada, Y
    Mamiya, K
    Yoshioka, S
    Irie, S
    Amamoto, T
    Nakamura, K
    Nakano, S
    Higuchi, S
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (06) : 647 - 653
  • [10] Ishizaki T, 1999, ALIMENT PHARM THERAP, V13, P27